G2GBIO, Inc.
456160
企业摘要
季度业绩走势
营业收入
营业利润率
市场偏好度
※ 点击图表可查看该月份的AI分析信息。
营业收入
合并
单独
营业利润
合并
单独
净利润
合并
单独
财务信息
保存为Excel
该期间没有财务信息数据。
~
季度
决算
*单位基准小数点第四位以下的数值标记为'0/-0'
财务指标预测
※ 本预测值是基于历史数据的AI简单估算值，可能与实际业绩存在差异。
企业概况
截至2026年6月
G2GBIO, Inc. is a leading company in the field of long-acting drug microsphere technology, and it has next-generation microsphere source technology that meets the development needs of half-life extended drugs, as well as global-level mass production process facilities. Because the company's technology is a highly versatile platform technology capable of carrying drugs of various substances, including synthetic drugs, peptide drugs, antibody drugs, and RNA therapeutics, it has secured technology commercialization achievements, such as licensing and joint development with numerous global pharmaceutical companies in the market, and the company's technology also enables CDO / CDMO businesses.
代表理事
Lee Huiyong
成立日期
2017年3月22日
法人类型
韩国创业板
行业分类
Manufacture of synthetic drug and other finished medicaments
法人注册号
16011-0451528
营业执照号
195-88-00664
电话号码
043-270-6011
传真号码
043-270-6099
网站
无
公司地址
21 Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do
产品与服务
评论